Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04973254 · ClinicalTrials.gov registry record · NA
Improving Treatment and Retention Adherence in Nontraditional Settings
A NA study, sponsored by Boston Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT04973254 is a NA study that has completed, run by Boston Medical Center. The registered enrollment target is 25 participants.
The verdict
NCT04973254, a NA study, has completed, sponsored by Boston Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a hybrid implementation-effectiveness study using both qualitative and quantitative methods. The research aims to examine whether providing a new, but approved, HIV once a month injection treatment \[Cabotegravir-Rilpivirine Long Acting (CAB-RPV LA)\] to individuals who are living with HIV outside of the standard doctors office or clinic increases adherence to treatment. This HIV monthly injections treatment which is already being delivered within the clinic setting, will be administered to participants in community partner spaces, reducing the barriers that having to present to a traditional clinic for treatment creates. Individuals who will receive the injection need to have a history of being unable to take their HIV oral medication, as well as other barriers to care that make it difficult to engage in a traditional clinic setting. These barriers may include, but are not limited to, homelessness, substance use, mental illness, and stigma around their diagnosis. Data will be collected on whether it was easier for the participants to receive care in a non-traditional setting, as well as whether the injection made it easier for them to remain adherent to their HIV medication in comparison to standard oral HIV medication.
Interventions
- OTHER CAB-RPV LA
- OTHER Standard treatment within an HIV clinic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-02-23 |
| Est. Completion | 2023-03-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04973254
The ClinicalTrials.gov registry entry for NCT04973254 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CAB-RPV LA is the first listed.
NCT04973254 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04973254 about?
NCT04973254 is a clinical study titled "Improving Treatment and Retention Adherence in Nontraditional Settings". This is a hybrid implementation-effectiveness study using both qualitative and quantitative methods. The research aims to examine whether providing a new, but approved, HIV once a month injection treatment \[Cabotegravir-Rilpivirine Long Acting (CAB-RPV LA)\] to individuals who are living with HIV o...
What is the current status of trial NCT04973254?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2022-02-23. Estimated completion is 2023-03-28.
What interventions are being tested in trial NCT04973254?
The interventions under investigation include: CAB-RPV LA (OTHER), Standard treatment within an HIV clinic (OTHER).
Who is sponsoring clinical trial NCT04973254?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.